Intuitive Surgical (ISRG) 🔴 Could Be Next? , 2.65% Spike! скачать в хорошем качестве

Intuitive Surgical (ISRG) 🔴 Could Be Next? , 2.65% Spike!

‪@WallStreetPulse01‬ Intuitive Surgical (ISRG) $446 🔴 Could $500 Be Next? 2.65% Spike! Intuitive Surgical (ISRG) surged 2.65% to $446.13 today—but is this just a short-term rally, or is the king of robotic surgery facing real competition? 🤔 In this video, we dive into: • Today’s $11.51 price jump and what it really means 📊 • The impact of Medtronic and Johnson & Johnson entering the robotic surgery space 🏥 • How hospitals’ capital constraints affect new da Vinci system placements 💸 • The difference between instrument sales (high-margin) vs. new systems • Institutional activity insights from 13F filings and what “smart money” is doing 💼 • The potential growth drivers: da Vinci 5, Ion system, AI & analytics 🚀 • The risks ahead: competition, reimbursement pressures, and high valuation ⚠️ Whether you’re using Fidelity, Schwab, Interactive Brokers, or Robinhood, this deep-dive analysis will help you understand ISRG beyond the headline numbers. 📌 Disclaimer: This video is for educational purposes only. Not financial advice. Always DYOR (Do Your Own Research). 👍 Like, Comment, and Share to help others understand the story behind Intuitive Surgical! #IntuitiveSurgical #ISRGStock #DaVinciRobot #MedTech #StockMarket #Investing #Robinhood #Fidelity #InteractiveBrokers #Schwab #ShortTermTrading #LongTermInvesting #StockAnalysis #MedicalRobotics #HealthcareInvesting #StockNews #WallStreet Intuitive Surgical, ISRG stock, ISRG stock analysis, ISRG today, ISRG stock price, ISRG news, ISRG forecast, ISRG prediction, da Vinci robot, ISRG short-term rally, ISRG institutional activity, ISRG 13F filings, ISRG stock surge, ISRG $446, ISRG growth story, ISRG market risk, ISRG competitors, Medtronic robotics, J&J Ottava, robotic surgery, robotic-assisted surgery, minimally invasive surgery, da Vinci system sales, da Vinci high-margin instruments, ISRG revenue, ISRG EPS, ISRG valuation, ISRG P/E ratio, ISRG market share, ISRG macro risks, ISRG hospital adoption, ISRG reimbursement risk, ISRG next-gen system, da Vinci 5, ISRG Ion system, robotic catheter, ISRG technological advantage, ISRG innovation, ISRG AI integration, ISRG surgical analytics, ISRG procedural growth, ISRG capital sales, ISRG instrument sales, ISRG service contracts, ISRG recurring revenue, ISRG competitive threat, ISRG MedTech, ISRG long-term growth, ISRG risks, ISRG institutional investors, ISRG hedge funds, ISRG technical breakout, ISRG RSI overbought, ISRG Fidelity, ISRG Schwab, ISRG Robinhood, ISRG Interactive Brokers, ISRG trading platform, ISRG online investing, ISRG active investing, ISRG self investing, ISRG fractional shares, ISRG stock review, ISRG earnings, ISRG guidance, ISRG analyst expectations, ISRG macro environment, ISRG interest rates, ISRG hospital spending, ISRG procedure volume, ISRG pricing power, ISRG competitive moat, ISRG patent expiry, ISRG market fragmentation, ISRG high-acuity procedures, ISRG low-acuity procedures, ISRG growth engines, ISRG capital expenditure, ISRG operational risk, ISRG portfolio, ISRG robo-advisor, ISRG long-term holding, ISRG short-term trade, ISRG valuation risk, ISRG stock update, ISRG US market, ISRG MedTech leader, ISRG surgical innovation, ISRG technology adoption, ISRG market narrative, ISRG investor insight, ISRG high-margin business, ISRG risk vs reward, ISRG 2025 outlook, ISRG stock review 2025, ISRG healthcare innovation, ISRG market dominance.